These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 20030193

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque.
    Frischer JM, Weigand SD, Guo Y, Kale N, Parisi JE, Pirko I, Mandrekar J, Bramow S, Metz I, Brück W, Lassmann H, Lucchinetti CF.
    Ann Neurol; 2015 Nov; 78(5):710-21. PubMed ID: 26239536
    [Abstract] [Full Text] [Related]

  • 43. Molecular mechanisms linking neuroinflammation and neurodegeneration in MS.
    Ellwardt E, Zipp F.
    Exp Neurol; 2014 Dec; 262 Pt A():8-17. PubMed ID: 24530639
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. The molecular basis of neurodegeneration in multiple sclerosis.
    Lassmann H, van Horssen J.
    FEBS Lett; 2011 Dec 01; 585(23):3715-23. PubMed ID: 21854776
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Multiple sclerosis: an infectious syndrome involving Chlamydophila pneumoniae.
    Stratton CW, Wheldon DB.
    Trends Microbiol; 2006 Nov 01; 14(11):474-9. PubMed ID: 16996738
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Grey matter pathology in multiple sclerosis.
    Bö L, Geurts JJ, Mörk SJ, van der Valk P.
    Acta Neurol Scand Suppl; 2006 Nov 01; 183():48-50. PubMed ID: 16637929
    [Abstract] [Full Text] [Related]

  • 56. Therapeutic Application of Monoclonal Antibodies in Multiple Sclerosis.
    Orthmann-Murphy JL, Calabresi PA.
    Clin Pharmacol Ther; 2017 Jan 01; 101(1):52-64. PubMed ID: 27804128
    [Abstract] [Full Text] [Related]

  • 57. The future of multiple sclerosis treatment.
    Cohen JA.
    J Neurol Sci; 2009 Feb 01; 277 Suppl 1():S55-61. PubMed ID: 19200869
    [Abstract] [Full Text] [Related]

  • 58. The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage.
    Brück W.
    J Neurol; 2005 Nov 01; 252 Suppl 5():v3-9. PubMed ID: 16254699
    [Abstract] [Full Text] [Related]

  • 59. Role of Mast Cells in the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis.
    Elieh-Ali-Komi D, Cao Y.
    Clin Rev Allergy Immunol; 2017 Jun 01; 52(3):436-445. PubMed ID: 28025778
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.